- PRO/AH/EDR> Chikungunya (03): Americas cases, vaccine
Mon, 24 May 2021 18:50:59 -0400
Chikungunya -- Brazil
Saint-Herblain-based Valneva SE announced on 12 Apr 2021 that it had completed recruitment for the pivotal Phase 3 clinical trial of its single-shot chikungunya vaccine candidate, VLA1553.
A total of 4131 adults aged 18 or above have been recruited across 44 sites in the USA for the VLA1553-301 trial, which was launched in September 2020. Participants will be followed for 6 months in the pivotal trial. If the trial results are positive, the trial is expected to support VLA1553's